Study: pioglitazone versus sulfonylureas in patients with type 2 diabetes
18 Sep, 2017 | 14:04h | UTCEffects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)
Commentary: Sulfonylureas, Pioglitazone Similarly Safe for Add-On Therapy in Type 2 Diabetes – Physician’s First Watch (free)